This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove .Net Remove Sales Remove Thousand Oaks Related Topics
Competition Blogging Pricing Media Acquisition Invest Funding Marketing Startup Develop More Related Topics >
article thumbnail

Amgen Acquires Otezla for $13.4 Billion

socalTECH

AUGUST 26, 2019

Thousand Oaks-based Amgen announced this morning that it is acquiring Otezla , the anti-inflammatory drug used to treat psoriasis and psoriatic arthritis, which is currently owned by Celgene Corporation , in a deal worth $13.4 billion net of anticipated future cash tax benefits. billion in sales in 2018. billion in cash.

Thousand Oaks 113
Thousand Oaks .Net Sales Acquisition 113
article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

AUGUST 26, 2016

The deal also includes a $175 million deferred payment due in 2019 and $850 million in downstream payouts tied to regulatory and sales targets. Frank Vinluan has more on Novan, which relied on a variety of high net worth individuals, rather than venture firms, to get to this point.

Pricing 40
Pricing Thousand Oaks Startup Research 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 5,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024